(AOF) – Innate Pharma shared new results from the phase 1/2 trial led by Sanofi evaluating NK cell engage SAR443579/IPH6101 in various blood cancers. It “continues to show clinical benefit, durable responses as well as a favorable safety profile in patients with relapsed-refractory acute myeloid leukemia,” explains the biotechnology company at the clinical stage. Five complete remissions were obtained at a dose of 1 mg/kg and lasting complete remissions (greater than 10 months) were observed in 3 patients.
LEXICON
Clinical trials (Phases I, II, III)
Phase I: testing of the molecule on a small scale on humans to evaluate its safety, its tolerance, its metabolic and pharmacological properties. Phase II: evaluation of tolerance and effectiveness on several hundred patients to identify side effects. Phase III: evaluation of the overall benefit/risk ratio in several thousand patients.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.